Oxford, United Kingdom
Sitryx is a dynamic player in the biopharmaceutical sector, leveraging the innovative capabilities of cell metabolism to pioneer novel, disease-modifying therapies focused on immuno-oncology and immuno-inflammation. Founded in 2018, the company operates from its headquarters in Oxford, UK.
The core of Sitryx’s expertise is enriched by a founding team composed of preeminent scientists from both the United States and Europe, renowned for their contributions to the burgeoning field of immunometabolism. With a robust and diverse pipeline across various stages of drug discovery, Sitryx holds significant promise for transforming traditional therapeutic approaches.
After securing seed funding from SV Health Investors, Sitryx attracted a notable $30 million Series A funding round, followed by a recent injection of $39 million in September 2023. Contributors to this round include prominent names like Longwood Fund, Sofinnova Partners, SV Health Investors, Eli Lilly, Oxford Science Enterprises, and GSK. This financial backing underscores the confidence in Sitryx’s potential and its strategy of targeting critical unmet needs in healthcare.
